Health & Fitness
Health and Fitness
Health and Fitness 
Wed, September 2, 2009
Tue, September 1, 2009
Mon, August 31, 2009
Basilea Pharmaceutica AG: Basilea Pharmaceutica Ltd.: FDA accepts for review the Complete Response submission to ceftobiprole N
BASEL, SWITZERLAND--(Marketwire - September 1, 2009) -
Basilea Pharmaceutica Ltd. (
The FDA informed Johnson & Johnson PRD that it considers the resubmission a complete, class 2 response. "We are pleased that the FDA has accepted for review the submission related to the Complete Response Letter. We look forward to the advancement of ceftobiprole through the FDA review process," commented Dr. Anthony Man, CEO.
Ceftobiprole is an anti-MRSA broad-spectrum cephalosporin antibiotic. It is marketed in Canada (ZEFTERA™) for the treatment of complicated skin and skin structure infections (cSSSI), including non-limb threatening diabetic foot infections without concomitant osteomyelitis and in Switzerland (Zevtera™) for the treatment of complicated skin and soft tissue infections (cSSTI) including diabetic foot infections without concomitant osteomyelitis.
Ceftobiprole is being developed through an exclusive worldwide collaboration between Basilea Pharmaceutica International Ltd. and Cilag GmbH International, a Johnson & Johnson company.
About Basilea
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Basilea's integrated research and development operations are currently focused on new antibacterial, antifungal and oncology agents to fight drug resistance and on the development of dermatology drugs. Basilea's products are targeted to satisfy high medical and patient needs in the hospital and specialty care setting. The company owns a diversified portfolio including two commercialized drugs (Toctino®, ZEFTERA™/ Zevtera™) and one investigational drug in phase III (isavuconazole). Toctino® (alitretinoin) is marketed in the United Kingdom, Denmark and Germany and is approved in Austria, Belgium, Finland, France, Luxemburg, the Netherlands and Spain. Alitretinoin has been recommended for approval in Italy and is under regulatory review in Canada, Switzerland and 15 additional European countries. Furthermore a phase III clinical trial on alitretinoin for the treatment of severe chronic hand eczema is ongoing in the U.S. Ceftobiprole is marketed in Canada under the brand name ZEFTERA™ and in Switzerland under Zevtera™. Ceftobiprole is under regulatory review in the U.S. and marketing applications are submitted in the EU and several other countries. The company has set up commercial organizations in UK, Denmark, Germany and Canada, while it is building sales and marketing organizations in other countries to commercialize alitretinoin and to co-promote ceftobiprole, subject to approval.
Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
+--------------------------------------------------------------+ | Media Relations | Investor Relations | |-----------------------------+--------------------------------| | Adesh Kaul | Barbara Zink, Ph.D. | | Head Public Relations & | Head Corporate Development | | Corporate Communications | +41 61 606 1233 | | +41 61 606 1460 | [ investor_relations@basilea.com ] | | [ media_relations@basilea.com ] | | +--------------------------------------------------------------+
This press release can be downloaded from [ www.basilea.com ]
The press release can also be downloaded from the following link: [ http://hugin.info/134390/R/1338502/319382.pdf ]
This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Copyright © Hugin AS 2009. All rights reserved.